Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Feb;25(2):153–156. doi: 10.1128/aac.25.2.153

Comparison of the effects of mezlocillin, carbenicillin, and placebo on normal hemostasis.

J O Ballard, S G Barnes, F R Sattler
PMCID: PMC185463  PMID: 6712199

Abstract

Mezlocillin was compared with carbenicillin and 0.9% NaCl as placebo in a double-blind manner to determine its effect in vivo on hemostasis in normal volunteers. Eighteen subjects were randomized to receive mezlocillin, 4 g every 6 h; carbenicillin, 7.5 g every 6 h; or placebo, 50 ml every 6 h, each given for 20 intravenous doses unless the template bleeding time after 10 doses was greater than 15 min. Template bleeding times were determined before the dose 1 and 1 h after doses 10 and 20. Five of six (83%) subjects receiving carbenicillin developed template bleeding time prolongation to greater than 21 min, and two of six (33%) subjects receiving mezlocillin and one of six (17%) subjects receiving carbenicillin had mild template bleeding time prolongations of less than 13 min. Coagulation studies (prothrombin time, partial thromboplastin time, and thrombin time) were normal in all subjects, and blood salicylate levels were negative. Thus, in standard therapeutic doses, mezlocillin was less likely than carbenicillin to prolong the template bleeding time above normal (P = 0.04) and, when prolongation occurred with mezlocillin, it was mild. These data support the selective use of mezlocillin in patients at increased risk for bleeding and who require therapy with an antipseudomonal penicillin.

Full text

PDF
153

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrassy K., Weischedel E., Ritz E., Andrassy T. Bleeding in uremic patients after carbenicillin. Thromb Haemost. 1976 Aug 31;36(1):115–126. [PubMed] [Google Scholar]
  2. Bodey G. P., Bolivar R., Fainstein V. Infectious complications in leukemic patients. Semin Hematol. 1982 Jul;19(3):193–226. [PubMed] [Google Scholar]
  3. Brown C. H., 3rd, Bradshaw M. J., Natelson E. A., Alfrey C. P., Jr, Williams T. W., Jr Defective platelet function following the administration of penicillin compounds. Blood. 1976 Jun;47(6):949–956. [PubMed] [Google Scholar]
  4. Brown C. H., 3rd, Natelson E. A., Bradshaw M. W., Alfrey C P., Jr, Williams T. W., Jr Study of the effects of ticarcillin on blood coagulation and platelet function. Antimicrob Agents Chemother. 1975 May;7(5):652–657. doi: 10.1128/aac.7.5.652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brown C. H., 3rd, Natelson E. A., Bradshaw W., Williams T. W., Jr, Alfrey C. P., Jr The hemostatic defect produced by carbenicillin. N Engl J Med. 1974 Aug 8;291(6):265–270. doi: 10.1056/NEJM197408082910601. [DOI] [PubMed] [Google Scholar]
  6. Copelan E. A., Kusumi R. K., Miller L., Fass R. J. A comparison of the effects of mezlocillin and carbenicillin on haemostasis in volunteers. J Antimicrob Chemother. 1983 May;11 (Suppl 100):43–49. doi: 10.1093/jac/11.suppl_c.43. [DOI] [PubMed] [Google Scholar]
  7. Eliopoulos G. M., Moellering R. C., Jr Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. Ann Intern Med. 1982 Nov;97(5):755–760. doi: 10.7326/0003-4819-97-5-755. [DOI] [PubMed] [Google Scholar]
  8. Gentry L. O., Jemsek J. G., Natelson E. A. Effects of sodium piperacillin on platelet function in normal volunteers. Antimicrob Agents Chemother. 1981 Apr;19(4):532–533. doi: 10.1128/aac.19.4.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Haburchak D. R., Head D. R., Everett E. D. Postoperative hemorrhage associated with carbenicillin administration. Report of two cases and review of the literature. Am J Surg. 1977 Nov;134(5):630–634. doi: 10.1016/0002-9610(77)90451-2. [DOI] [PubMed] [Google Scholar]
  10. Kohler R. B., Foerster L. A., Wheat L. J., Williams J. M., Reynolds J., Norton J. Piperacillin and gentamicin v carbenicillin and gentamicin for treatment of serious gram-negative infections. Arch Intern Med. 1982 Jul;142(7):1335–1337. [PubMed] [Google Scholar]
  11. McClure P. D., Casserly J. G., Monsier C., Crozier D. Carbenicillin-induced bleeding disorder. Lancet. 1970 Dec 19;2(7686):1307–1308. doi: 10.1016/s0140-6736(70)92264-6. [DOI] [PubMed] [Google Scholar]
  12. Pevine P. L. Editorial: Platelet-function tests: predictive value. N Engl J Med. 1975 Jun 19;292(25):1346–1347. doi: 10.1056/NEJM197506192922508. [DOI] [PubMed] [Google Scholar]
  13. Somani P., Smith M. R., Gohara A., Kapila K. The effects of mezlocillin, ticarcillin and placebo on blood coagulation and bleeding time in normal volunteers. J Antimicrob Chemother. 1983 May;11 (Suppl 100):33–41. doi: 10.1093/jac/11.suppl_c.33. [DOI] [PubMed] [Google Scholar]
  14. Wade J. C., Schimpff S. C., Newman K. A., Fortner C. L., Standiford H. C., Wiernik P. H. Piperacillin or ticarcillin plus amikacin. A double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med. 1981 Dec;71(6):983–990. doi: 10.1016/0002-9343(81)90324-7. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES